[關(guān)鍵詞]
[摘要]
目的 探討坤泰膠囊聯(lián)合醋酸亮丙瑞林緩釋微球治療子宮內(nèi)膜異位癥的安全性和有效性。方法 選取鄭州頤和醫(yī)院2015年8月-2016年8月收治的子宮內(nèi)膜異位癥患者183例,隨機分成對照組(91例)和治療組(92例)。對照組患者皮下注射注射用醋酸亮丙瑞林緩釋微球,于經(jīng)期開始5 d內(nèi)注射3.75 mg,每28天注射1次;治療組在對照組的基礎(chǔ)上口服坤泰膠囊,4粒/次,3次/d,兩組均連續(xù)治療3個月。分析評價兩組患者治療前后臨床療效、體內(nèi)性激素水平、Kuppeman評分、VAS評分以及不良反應(yīng)情況。結(jié)果 治療后,對照組和治療組總有效率分別為82.42%、96.74%,兩組比較差異有統(tǒng)計學意義(P<0.05)。治療后,兩組患者雌二醇、黃體生成激素以及卵泡生成素水平均明顯降低(P<0.05);且治療組患者性激素水平明顯優(yōu)于對照組患者(P<0.05)。治療后,兩組患者Kuppeman評分明顯升高,VAS評分明顯降低,同組治療前后比較差異具有統(tǒng)計學意義(P<0.05);且治療組患者Kuppeman評分和VAS評分改善情況要明顯優(yōu)于對照組患者,兩組比較差異具有統(tǒng)計學意義(P<0.05)。治療期間對照組患者不良反應(yīng)發(fā)生率為37.36%,顯著高于治療組的15.22%,兩組比較差異具有統(tǒng)計學意義(P<0.05)。結(jié)論 坤泰膠囊聯(lián)合醋酸亮丙瑞林緩釋微球治療子宮內(nèi)膜異位癥療效好、安全性高,具有一定的臨床推廣應(yīng)用價值。
[Key word]
[Abstract]
Objective To explore the safety and efficacy of Kuntai Capsules combined with leuramide in treatment of endometriosis. Methods Patients (183 cases) with endometriosis in Zhengzhou Yihe Hospital Affiliated to Henan University from August 2015 to August 2016 were randomly divided into control (91 cases) and treatment (92 cases) groups. Patients in the control group were sc injected with Leuprorelin Acetate Microspheres Sustained Release for injection, 3.75 mg injected in 5 d after menstruation, once every 28 d. Patients in the treatment group were po administered with Kuntai Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for three months. After treatment, the clinical efficacy, sex hormone level, Kuppeman and VAS scores, and adverse reaction in two groups before and after treatment were analyzed and evaluated. Results After treatment, the clinical efficacies in the control and treatment groups were 82.42% and 96.74% respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of estradiol, luteinizing and follicle stimulating hormone in two groups were significantly decreased (P < 0.05). And the sex hormone level in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, Kuppeman scores in two groups were significantly increased, but VAS score was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the improvement effect of Kuppeman and VAS scores in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). During the treatment, the adverse reaction in the control group was 37.36%, which was significantly higher than 15.22% in the treatment group, and there were differences between two groups (P < 0.05). Conclusion Kuntai Capsules combined with leuramide have good curative effect and safety in treatment of endometriosis, which has a certain clinical application value.
[中圖分類號]
[基金項目]